Skip to main content
. 2024 Aug 21;9(9):103677. doi: 10.1016/j.esmoop.2024.103677

Figure 2.

Figure 2

Progression-free survival (PFS) and overall survival (OS) in BRAFmt metastatic colorectal cancer (mCRC) cases when treated with or without anti-EGFR. (A) PFS according to treatment with or without anti-EGFR in BRAFmt mCRC. (B) OS according to treatment with or without anti-EGFR in BRAFmt mCRC. P values correspond to Cox regression. BRAFmt, BRAFV600E mutant/RAS wild-type; CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio.